Mini Review
Published on 13 Jan 2023
Open questions in human lung organoid research
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1083017
- 6,275 views
- 8 citations
Type at least 3 characters
605 articles
Original Research
Published on 12 Jan 2023
Fast cycling of intermittent hypoxia in a physiomimetic 3D environment: A novel tool for the study of the parenchymal effects of sleep apnea
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1081345
- 2,191 views
Original Research
Published on 09 Jan 2023
Dang Gui Bu Xue Tang, a conventional Chinese herb decoction, ameliorates radiation-induced heart disease via Nrf2/HMGB1 pathway
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1086206
- 3,058 views
- 7 citations
Original Research
Published on 06 Jan 2023
Enhanced secretion of hepatocyte growth factor in human umbilical cord mesenchymal stem cells ameliorates pulmonary fibrosis induced by bleomycin in rats
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1070736
- 2,818 views
- 11 citations
Original Research
Published on 06 Jan 2023
Tetramethylpyrazine ameliorates acute lung injury by regulating the Rac1/LIMK1 signaling pathway
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1005014
- 3,841 views
- 13 citations
Correction
Published on 04 Jan 2023
Corrigendum: Investigating the effects of Liushen Capsules (LS) on the metabolome of seasonal influenza: A randomized clinical trial
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1036927
- 1,286 views
- 2 citations
Original Research
Published on 22 Dec 2022
FGF10 ameliorates lipopolysaccharide-induced acute lung injury in mice via the BMP4-autophagy pathway
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1019755
- 4,096 views
- 6 citations
Correction
Published on 16 Dec 2022
Corrigendum: Effect of M6A regulators on diagnosis, subtype classification, prognosis and novel therapeutic target development of idiopathic pulmonary fibrosis
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1117317
- 1,086 views
Review
Published on 12 Dec 2022
Emerging toolset of three-dimensional pulmonary cell culture models for simulating lung pathophysiology towards mechanistic elucidation and therapeutic treatment of SARS-COV-2 infection
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1033043
- 3,577 views
- 1 citation
Editorial
Published on 07 Dec 2022
Editorial: Antiviral drugs and vaccines against important human respiratory viruses
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1082652
- 1,216 views
Correction
Published on 02 Dec 2022
Corrigendum: Danshensu methyl ester enhances autophagy to attenuate pulmonary fibrosis by targeting lncIAPF–HuR complex
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1086927
- 1,773 views
Review
Published on 02 Dec 2022
Human matters in asthma: Considering the microbiome in pulmonary health
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1020133
- 6,641 views
- 7 citations
Original Research
Published on 29 Nov 2022
Inhaled platelet vesicle-decoyed biomimetic nanoparticles attenuate inflammatory lung injury
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1050224
- 6,183 views
- 15 citations
Original Research
Published on 29 Nov 2022
Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1055702
- 2,531 views
- 4 citations
Original Research
Published on 28 Nov 2022
Effect of M6A regulators on diagnosis, subtype classification, prognosis and novel therapeutic target development of idiopathic pulmonary fibrosis
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.993567
- 3,431 views
- 11 citations
Original Research
Published on 23 Nov 2022
Erythromycin attenuates oxidative stress-induced cellular senescence via the PI3K-mTOR signaling pathway in chronic obstructive pulmonary disease
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1043474
- 3,748 views
- 13 citations